Though increasing numbers of studies has explored the potential role of FADS2 in the progression and treatment of cancer over the past decade, systematic pan-cancer studies are still lacking to fully demonstrate its oncogenic impact and prognostic value [15–18]. This evidence concerns the gene FADS2 and cancer.